Research Article

Comparison of the Donor Age-Dependent and In Vitro Culture-Dependent Mesenchymal Stem Cell Aging in Rat Model

Katarzyna Siennicka, Aleksandra Żołocińska, Tomasz Dębski, and Zygmunt Pojda

Department of Regenerative Medicine, Maria Skłodowska-Curie National Research Institute of Oncology, Warsaw, Poland

Correspondence should be addressed to Katarzyna Siennicka; katarzyna.siennicka@pib-nio.pl

Received 22 October 2020; Revised 12 January 2021; Accepted 27 April 2021; Published 15 May 2021

Clinical experiments suggest that mesenchymal stem cells (MSCs) may be useful for tissue repair therapies or treatment of the autoimmune disorders. There is still lack of consensus concerning the age limit of MSC donors, majority of researchers suggest the autologous MSC therapies of patients not exceeding age limit of 55-60 yrs. The purpose of our study was to compare the selected parameters of MSCs from adipose tissue (adipose stem cell, ASC) collected from young and old rats of ages corresponding to patient’s ages 25 yrs. and 80 yrs., respectively. The differences of parameters of ASCs from young and old animals were compared with the differences between ASCs from short-term (3 passage) and long-term (30 passage) in vitro culture. Cell morphology, surface marker expression, growth potential, metabolic activity, β-galactosidase activity, clonogenic potential, angiogenic potential, and differentiation ability of ASCs from young and aged animals and from in vitro cultures at 3rd and 30th passages were compared and analyzed. It may be concluded that ASCs may be applied for autologous transplantations in aged patients. Comparison of ASC aging dynamics depending on host aging or in vitro culture duration suggests that long-term in vitro culture may affect ASCs more than natural aging process of their host. We suggest that ASCs expanded in vitro prior to their clinical use must be carefully screened for the possible aging effects resulting not only from donor age, but from the duration of their in vitro culture.

1. Introduction

The ClinicalTrials.gov database search (2020) results in 1071 clinical experiments with the use of mesenchymal stem (stromal) cells (MSCs) for treatment of the wide variety of injuries and diseases. Out of this number, 391 trials include autologous MSC treatment. There is no consensus on the age limit for the MSC donors. Several reports confirm MSC aging (β-galactosidase activity, telomere length, and telomerase activity) related to host age, but the data on the therapeutical usefulness of MSCs from the senile donors are insufficient [1–6]. Even more limited is the information concerning the relationship between in vitro aging caused by the long-term in vitro MSC expansion and their morphological and functional parameters which are customary analyzed in the process of the qualification of MSCs for therapeutic applications.

We used the rat model, corresponding to the human ASC (adipose stem cell, subclass of mesenchymal stem cell) donors of the age of 25 yrs. and 80 yrs. for the comparison of the cell parameters commonly attributed to age (β-galactosidase activity) and parameters important for therapeutic usefulness of ASC for the clinical applications (proliferative potential, metabolic activity, differentiation into adipo-, chondro-, and osteogenic lineages, and the capacity to induce angiogenesis [7–9]. For the comparison of ASC “aging” resulting from the increase of donor age and “aging” resulting from the in vitro culture duration, we compared ASCs, collected from young (6 mth) and aged (2 yrs.) rats from short-term (3 passage) and long-term (30 passage) in vitro culture and long-term (30 passage) in vitro culture.

2. Materials and Methods

2.1. Collection and Isolation of ASCs from Rat Adipose Tissue. Male Wistar Albino Glaxo inbred rats aged 6 mth (309.8 ± 21.6 g) and 2 yrs. (353.5 ± 19.1 g) were used throughout experiment. Inhalation method (isoflurane overdose) was used for euthanasia of animals. White adipose tissue was collected from inguinal, perigonadal, and perirenal...
regions. Pooled adipose tissue from different regions of each animal was digested in 0.075% solution of collagenase (from *Clostridium histolyticum*, Sigma-Aldrich, USA) in phosphate-buffered saline (PBS, Life Technologies Co, USA) for 30 min at 37°C. Resulting suspension was mixed with 10% FBS (Fetal Bovine Serum, Life Technologies Co, USA), filtered and washed with PBS. Cells numbers and viability were tested using ADAM-MC automated cell counter (NanoEnTek Inc., USA), cells were suspended in DMEM medium (Life Technologies, USA) plus 10% FBS and used for further experiments. All animal experiments were approved by the II Local Bioethical Committee in Warsaw (Approval number: 71/215/30/06/2015) and performed according to the Guidelines for the Regulation of Animal Experiments.

2.2. In Vitro Culture of Rat ASCs. Cells were cultured in 75 cm² plastic flasks (Nunclon, USA), 5 × 10⁵ cells per flask, 37°C, 5% CO₂, and 95% humidity. After achieving 80% confluence, cultures were trypsinized (0.25% trypsin, Life Technologies Co, USA), resuspended in DMEM +10% FBS, and transferred to the new culture flask.

2.3. Evaluation of MSC Morphology (Cell Shape, Granulation, Surface Markers). Cell morphology was evaluated using Juli™ Stage Real-Time History Recorder (NanoEnTek Inc., USA), and cell dimensions and shape were compared. Cell granulation and expression of surface markers were analyzed using flow cytometry (FACS Calibur and program CellQUEST pro, Becton Dickinson, USA). Expression of CD29, CD11b, CD90, CD45, and CD34 surface antigens (markers) was quantitatively evaluated, and cell granulation was estimated using forward scatter (FSC) and side scatter (SSC) parameters.

2.4. Doubling Time and Growth Rate. ASCs were seeded on multiwell plates in proportion of 1 × 10⁴ cells per 9.6 cm² flat well surface. Cultures were performed in the chamber with controlled gas composition (5% CO₂-enriched atmosphere, 95% humidity) (CMV1500 Baker Russkin Co, USA), equipped with the microscope system enabling constant picture monitoring (Juli™ Stage NanoEnTek Inc., USA) using program Real-Time History Recorder. The performed determinations allowed for microscopic observations, taking photos, and counting cells always in the same area, at different time points. Observations and photographic recordings of the marked areas were carried out every 5 hours until the cells were fully confluent. From the designated and registered areas, cells were counted from the moment of their adhesion to the plastic until the end of the experiment, taking into account the recording time. Growth rate and doubling time were calculated using free program Doubling Time Online Calculator (http://www.doubling-time.com/compute_more.php).

2.5. Metabolic Activity. Metabolic (mitochondrial) activity of ASCs was measured using commercially available MTS test kit Cell Titet 96® Aqueous One Solution Cell Proliferation Assay (Promega, USA). Product of the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide to water-soluble formazan was measured using spectrophotometer Multiscan GO (Thermo Fisher Scientific, USA). Quantity of formazan product as measured by the amount of 490 nm absorbance is directly proportional to the number of living cells in culture. 5 × 10⁴ cells per well were seeded on 24-well plates and cultured in DMEM supplemented by 10% FBS. Metabolic activity was tested in 3 time points: after 24h, 7 days, and 21 days of culture.

2.6. Clonogenic Potential. Cell clonogenic potential (CFU-F test) was performed in 6-well culture plates (2 ml DMEM +10% FBS, 2.6 × 10² ASC per well, 5% CO₂, 37°C, 95% humidity, and 7 d culture). Cell colonies (>50 cells/colony) were scored under inverted microscope following May-Grünwald/Giemsa staining.

2.7. ASC Differentiation (Adipo-, Osteo-, and Chondrogenesis). Plastic-adherent ASCs were stimulated into adipo-, osteo-, and chondrogenesis differentiation by the use of commercially available differentiating media (LONZA, Switzerland), according to producer’s protocols (adipogenic induction medium and adipogenic maintenance medium for adipogenesis, osteogenic induction medium for osteogenesis, and complete chondrogenic induction medium for induction of chondrogenic differentiation). Effects of adipogenic differentiation were evaluated under microscope following staining of cultures with Oil Red (Sigma-Aldrich, USA) and using real-time PCR for CEBPA (Rn00560963_s1), ADIPOQ (Rn00595230_m1), and PPARy (Rn00440945_m1) gene expression specific for adipogenesis. Osteogenic differentiation was evaluated after cell staining with Alizarin Red S (Sigma-Aldrich, USA) and using real-time PCR for osteogenesis-specific genes ALPL (Rn01516028_m1), RUNX2 (Rn01512298_m1), and IBSP (Rn00561414_m1). Chondrogenic differentiation was evaluated under microscope after Masson Trichrome staining and real-time PCR for chondrogenesis-specific genes COMP (Rn00563255_m1), SOX9 (Rn01751069_m1), and ACAN (Rn00573424_m1). Gene expression was determined using real-time PCR (Roche LightCycler®96, RFN). The reaction mixture (20μl) contained 9μl of reverse transcription cDNA (concentration 100-150 μl of suspended in nuclease-free water (Sigma-Aldrich, USA)), 10μl of TaqMan Universal PCR Master Mix, NoAmpErase UNG (2x), and 1μl of TaqMan probe. The reaction steps were as follows: denaturation step—1 cycle: 50°C for 120 s and 95°C for 600 s followed by 40 cycles of elongation step: 95°C for 15 s and 60°C for 60s, and cooling step at 37°C. GAPDH (Rn01775763_g1) and ACTB (Rn00667869_m1) were used as reference genes in each sample.

2.8. Angiogenic Potential and Paracrine Proangiogenic Effect of ASC

2.8.1. Angiogenic Potential of ASCs. Angiogenic potential of ASC was evaluated by the application of 2 independent tests: tubule formation assay and sprouting from 3D spheroids assay. Tubule formation assay was performed using 96-well plates covered with Matrigel® (Corning®, USA) with 1 × 10⁴ cells per well added and suspended in 100 μl of EGM-2 (LONZA, Switzerland), incubated for 20 h (37°C, 5% CO₂, and 95% humidity). Test results were evaluated by identification of the formation of tubules under inverted microscope.
3D sprouting assay was performed in the round-bottom 96-well plates. Spheroid formation was observed after 24 h incubation of 750 cells per well in 1:4 mixture of methylcellulose (R&D Systems, USA) and EGM-2 medium.

2.8.2. Stimulatory (Paracrine) Angiogenic Effect of ASCs on HUVEC Cells. Stimulatory effects of conditioned media from ASC on the HUVEC cell cultures were tested. Positive control cultures were performed in 6-well HUVEC cell cultures in Matrigel in EGM-2 medium plus 0.5% FBS, and negative control cultures were done similarly but in EGM-2 medium plus 0.5% FBS added. HUVEC cells were incubated for 20 h (37°C, 5% CO₂, and 95% humidity). Conditioned media were collected from ASC (young or senile rats, 3 passage or 30th passage) cultures (6-well plates, 3 x 10⁵ cells/well, Matrigel plus 0.5% FBS added, 37°C, 5% CO₂, and 20 h incubation) and added into HUVEC cultures (6-well plates, Matrigel plus conditioned medium, 37°C, 5% CO₂, 95% humidity, and 20 h). The criterion of the positive paracrine effect of ASC on HUVEC cells was tubule formation in HUVEC cultures observed under visible light contrast phase inverted microscope (Olympus CKX41, Japan).

2.9. β-Galactosidase (SA-β-Gal) Activity. ASCs (2 x 10⁴ cells/well) were cultured for 24 h in 24-well plates (37°C, 5% CO₂, and 95% humidity) and tested for β-galactosidase activity with Senescence β-Galactosidase Staining Kit (Cell Signaling Technology) according to producer’s manual. Cell ratio of blue-stained versus nonstained cells was scored under Nikon Eclipse Ti microscope (Japan) using the computer program Nis-Elements AR Analysis 4.00.12.

2.10. Statistical Analysis. Statistical analysis was performed using Statistica 13 PL computer program. After getting the results with Shapiro-Wilk test, data were analyzed with one- or two-factor ANOVA variance tests, ANOVA repeated-measures analysis of variance, variance homogeneity, and post hoc Tukey HSD and NIR tests. Comparison of means of specific group with controls was done using Dunnett test. Statistically significant differences were analyzed at p < 0.05 level (graphic descriptions: statistical significance levels described as “p < 0.05, **p < 0.01, and ***p < 0.001; M: statistical mean; SE: standard error).

3. Results

3.1. ASC Morphology. We did not observe any significant differences between CD29 and CD90 surface marker expression between young (6 mth) and old (2 yrs.) donors and between cells from short-term (3 passage) and long-term (30 passage) in vitro cultures (Figure 1(a)). The transition of cell shape from fibroblast-like to epithelial-like was typical for the in vitro aging of ASC cultures, and the pattern of this phenomenon was similar for ASCs derived both from young and old donors (Figure 1(b)). Adversely, the granularity of ASCs increased with the donor age, but was independent from the in vitro culture duration (Figure 1(c)).
Figure 1: Continued.
compared to old donors and to short-term in vitro cultures (Figure 4(a)). Number of tubules produced by spheroids formed by ASCs (Figure 4(b)) were higher in long-term cultures both from young and old donors, and all ASC-formed spheroids produced more tubules than HUVEC control cultures ($p < 0.05$, Figure 4(b)).

Summarized length of tubules produced by single spheroid was higher for young versus old donors and in both groups higher for long-term versus short-term cultures and higher in ASC-formed spheroids than HUVEC-formed spheroids ($p < 0.05$).

Mean tube lengths were higher in spheroids formed by ASCs from young donors, higher in spheroids formed by ASCs from long-term cultures, and all types of ASC-formed spheroid forming tubules are significantly longer than HUVEC controls ($p < 0.05$).

Control HUVEC cultures in Matrigel (0.5% FBS) did not produce tubules, and addition of ASC-conditioned media resulted in tubule production; no statistically significant differences between the effects of conditioned media from ASCs from young or old donors and short-term or long-term cultures were observed (Figure 4(c)).

When summarizing the angiogenesis test results, it may be concluded that both ASCs per se and ASC culture-
conditioned media express proangiogenic potential. Angiogenesis in vitro tests (Matrigel culture tubule formation and tubule formation capacity by spheroids formed by ASCs) suggest higher angiogenic potential of ASCs from young versus old donors and from long-term versus short-term cultures, but the differences are barely statistically significant and both young donor-derived and old donor-derived ASCs express proangiogenic capacity.

3.5. Endogenous β-Galactosidase Activity in ASC In Vitro Cultures. Highest SA-β-Gal levels were observed in ASCs from long-term cultures from old donors (Figure 5(a)). Levels of SA-β-Gal of old donors were higher when compared to their young counterparts and higher in ASCs from long-term cultures than short-term cultures. Statistical analysis of results (Figure 5(b)) allows to conclude at high levels \( p < 0.01 \) of statistical significance that the differences between SA-β-Gal levels in ASC cultures of young and old donors are smaller than the differences in SA-β-Gal levels in ASCs’ short-term and long-term cultures, and the phenomenon is not depending on the cell donor age.

3.6. Result Summary. Summarized results are presented in Table 2. Differences in the analyzed ASC parameters are divided into the differences between ASCs derived from the young of old donors (6 mth or 2 yrs. old rats) and the differences between ASCs cultured for the short (3 passages) or long (30 passages) time in vitro. *\( p < 0.05 \).

4. Discussion

ASC belongs to the class of progenitor cells [10, 11] and does not have the “stemness” capacity, as the consequence it ages similarly (although slower) than the other adult somatic cells. There are some data suggesting the presence of the “anti-aging” mechanisms, like the activity of telomerase, but most
Figure 3: Continued.
Figure 3: Continued.

- **ALPL**
  - Relative expression of mRNA (RQ)
  - 6 month-old ASC from 6 mth old donors, passage 3
  - 2 years-old ASC from 2 yrs old donors, passage 3
  - 6 month-old ASC from 6 mth old donors, passage 30
  - 2 years-old ASC from 2 yrs old donors, passage 30

- **RUNX2**
  - Relative expression of mRNA (RQ)
  - 6 month-old ASC from 6 mth old donors, passage 3
  - 2 years-old ASC from 2 yrs old donors, passage 3
  - 6 month-old ASC from 6 mth old donors, passage 30
  - 2 years-old ASC from 2 yrs old donors, passage 30

- **IBSP**
  - Relative expression of mRNA (RQ)
  - 6 month-old ASC from 6 mth old donors, passage 3
  - 2 years-old ASC from 2 yrs old donors, passage 3
  - 6 month-old ASC from 6 mth old donors, passage 30
  - 2 years-old ASC from 2 yrs old donors, passage 30

(b)
published data documents the age-related changes (limited lifespan, telomere shortening, etc.) of the ASC population. Our experiments confirmed the aging and mortality of ASC population; on the other hand, we observed longer than average somatic cell in vitro proliferative potential of ASCs (over 30 in vitro passages, up to 6 months in vitro cell culture duration) and some intriguing phenomena like the increase of cell clonality (CFU-F percentage) along the cell culture duration.

Our results confirm the findings of other authors that ASCs are cells in between typical adult somatic cell population and stem cells. Wistar Albino Galaxo strain is indeed frequently used as a model for epilepsy research. However, as we published before, no differences were detected between adipose-derived stem cells (ASCs) isolated from Wistar Albino Galaxo and Lewis rat tissue [12]. Quantity, phenotype, clonogenic, and differentiation potential of cells isolated from different localizations of adipose tissue from WAG and LEW/W rat strains were compared.

We have analyzed these cellular parameters, which are commonly recognized as important for the use of ASCs for therapeutic purposes in regenerative medicine. ASCs are widely used for the clinical experiments (not routine clinical applications in US and Europe) for the tissue regeneration purposes, implant construction, local stimulation of tissue healing, or the modulation of the host immune system activity [13–26]. Despite of many in vitro or in vivo experiments, there is still lack of consensus concerning the age limit of the donors of ASCs for clinical applications. The situation is similar as the
Figure 4: Continued.
Figure 4: Continued.
beginnings of bone marrow transplantations, when both the age of bone marrow donor and the age of marrow recipients were initially set at the safe low level and stepwise increased along with gaining theoretical and clinical experience.

For the purpose of the study, we have selected several cell parameters, which are important for the attempted role of ASC in tissue repair. These parameters are also most commonly considered in the theoretical and translational studies on ASC role in tissue microenvironment regulation and tissue repair.

It is the common knowledge, confirmed by multiple experimental data, that somatic cell populations are aging in parallel with the lifespan of the host, and first of two aims of our study was to evaluate the age-related differences between ASCs derived from the 6 mth old rats (approximate equivalent of human age of 25 yrs.) and 2 yrs. old rats (corresponding to human age of 80 yrs.).

Our second purpose of the study was to evaluate the impact of the ASC in vitro cell culture duration on cell aging. The mechanism of cell aging resulting from multiple cell divisions is commonly known, one of the most important being the shortening of chromosome telomeres up to the level which arrest further cell divisions (the Hayflick rule). ASCs (along with the other members of the MSC family) are rather slowly dividing cells in vivo, and their increased activity is stimulated by the local tissue injury and repair processes [27, 28]. In vitro ASCs are frequently “expanded” in bioreactors, and the technique enabling to obtain higher cell numbers for clinical purposes and the published data on the impact of the culture duration on the quality of bioreactor-expanded cells are rather scarce and focused mostly on the analysis of possibly chromosomal abnormalities or possible cancerogenic transformation. Our data show that ASC aging caused by prolonged in vitro culture may be as important for their clinical applications, as the advanced age of the cell donor.

Like other authors, we did not observe any significant differences in the expression of ASC surface markers CD29 and
CD90 depending both on donor animal age or in vitro cell culture duration [11, 29]. Both markers are used for classification of cells into MSC category, and their constant presence in all experimental groups confirms that ASCs, nevertheless of the animal age or in vitro culture duration, maintain their morphology and may be identified or FACS sorted on the basis of their surface markers. FACS analysis revealed that ASCs from aged individuals contain more granular structures than their counterparts from young donors—phenomenon nonexisting in “culture-old” versus “culture-young” cells. More granularity in ASC is probably associated with a greater mass of lysosomes in aged cells [30]. β-Galactosidase activity levels also correlate with the increase in lysosome mass (SA-β-Gal). Cell doubling time (growth rate) did not differ depending on cell donor age or cell culture duration. ASC metabolic activity, measured by MTS test, did not differ in ASCs derived from young and old animals. Similarly, there was no difference in ASC clonogenic potential (CFU-F test) of ASCs from young and old donors. Surprisingly, the metabolic activity and the percentage of colony-forming cells were significantly increased after long-term in vitro culture. The intriguing observation, to our knowledge not described yet by the other authors, may suggest that long-term in vitro culture allows to select less differentiated ASC subpopulation, enriched in clonogenic cells with higher metabolic activity. Such mechanism was
observed in the other stem/progenitor cell populations stimulated for self-renewal activity, for example, during hematopoietic system regeneration after sublethal host irradiation or bone marrow transplantation. Age-related increase of the adipogenic and chondrogenic ASC potential in vivo and parallel decrease of osteogenic potential during aging of individuals were observed by the others, and we succeeded to confirm similar regularities for adipogenic- and chondrogenic ASC aging in vitro model of cell aging dependent on cell culture duration [31–37]. Real-time PCR did not give consistent statistically significant results for adipogenesis-related marker genes.

ASCs are actively forming the elements of new blood vessels in vitro and are capable to stimulate neoangiogenesis in vivo. Several tests for angiogenic potential of ASC confirmed higher proangiogenic potential of ASCs from young rats when compared to ASCs from old animals. In contrary, 2 of 3 tests for angiogenic potential of ASCs in vitro (tubule formation potential and single spheroid summarized tubule length) have shown higher proangiogenic activity of cells from long-term cultures than of their short-term culture-derived counterparts. Another parameter (mean tubule length) in opposite suggested stronger proangiogenic potential of short-term culture-derived cells from long-term cultures of ASCs resulting from long-term culture (e.g., bioreactor expansion for clinical purposes) may be equal or more intense than MSC aging resulting from advanced age of cell donors.

5. Conclusions
It may be concluded that the donor age does not affect phenotypical nor functional characteristics of mesenchymal stem cells to the extent which would affect their usefulness for the regenerative medicine applications. In vitro aging processes of MSCs resulting from long-term culture (e.g., bioreactor expansion for clinical purposes) may be equal or more intense than MSC aging resulting from advanced age of cell donors.

Data Availability
Data are available on request from the authors.

Conflicts of Interest
The authors declare no competing interests.

Acknowledgments
This work was further supported by Maria Sklodowska-Curie National Research Institute of Oncology subsidy from Ministry of Science and Higher Education.

References

[1] J. D. Kretlow, Y. Q. Jin, W. Liu et al., "Donor age and cell passage affects differentiation potential of murine bone marrow-derived stem cells," BMC Cell Biology, vol. 9, no. 1, p. 60, 2008.
[2] A. Stolzing, E. Jones, D. McGonagle, and A. Scutt, "Age-related changes in human bone marrow-derived mesenchymal stem
cells: consequences for cell therapies,” *Mechanisms of Ageing and Development*, vol. 129, no. 3, pp. 163–173, 2008.

[3] M. S. Choudhery, M. Khan, R. Mahmood, A. Mehmoond, S. N. Khan, and S. Riazuddin, “Bone marrow derived mesenchymal stem cells from aged mice have reduced wound healing, angiogenesis, proliferation and anti-apoptosis capabilities,” *Cell Biology International*, vol. 36, no. 8, pp. 747–753, 2012.

[4] D. Duscher, R. C. Rennert, M. Januszyk et al., “Aging disrupts cell subpopulation dynamics and diminishes the function of mesenchymal stem cells,” *Scientific Reports*, vol. 4, p. 7144, 2014.

[5] C. C. Wyles, M. T. Houdek, A. Behfar, and R. J. Sierra, “Mesenchymal stem cell therapy for osteoarthritis: current perspectives,” *Stem Cells and Cloning: Advances and Applications*, vol. 28, no. 8, pp. 117–124, 2015.

[6] M. A. Szychlinska, M. J. Stoddart, U. D’Amora, L. Ambrosio, M. Alii, and G. Musumeci, “Mesenchymal stem cell-based cartilage regeneration approach and cell senescence: can we manipulate cell aging and function?,” *Tissue Engineering Part B: Reviews*, vol. 23, no. 6, pp. 529–539, 2017.

[7] R. Quinn, “Comparing rat’s to human’s age; How old is my rat in people years?,” *Nutrition*, vol. 21, no. 6, pp. 775–777, 2005.

[8] P. Sengupta, “The laboratory rat: relating its age with human’s,” *International Journal of Preventive Medicine*, vol. 4, no. 6, pp. 624–630, 2013.

[9] N. A. Andreollo, E. F. dos Santos, M. R. Araujo, and L. R. Lopes, “Rat’s age versus human’s age: what is the relationship?,” *ABCD-Arquivos Brasileiros de Cirurgia Digestiva-Brazilian Archives of Digestive Surgery*, vol. 25, no. 1, pp. 49–51, 2012.

[10] E. M. Horwitz, K. Le Blanc, M. Dominici et al., “Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement,” *Cytotherapy*, vol. 7, no. 5, pp. 393–395, 2005.

[11] M. L. Dominici, K. Le Blanc, I. Mueller et al., “Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement,” *Cytotherapy*, vol. 8, no. 4, pp. 315–317, 2006.

[12] A. Zolocinska, K. Siennicka, T. Debski et al., “Comparison of mouse, rat and rabbit models for adipose-derived stem cells (ASC) research,” *Current Research in Translational Medicine*, vol. 68, no. 4, pp. 205–210, 2020.

[13] W. S. Kim, B. S. Park, S. H. Park, H. K. Kim, and J. H. Sung, “Antioxidant effect of adipose-derived stem cell: activation of dermal fibroblast by secretory factors,” *Journal of Dermatological Science*, vol. 53, no. 2, pp. 96–102, 2009.

[14] W. S. Kim, B. S. Park, and J. H. Sung, “Protective role of adipose-derived stem cells and their soluble factors in photocaging,” *Archives of Dermatological Research*, vol. 301, no. 5, pp. 329–336, 2009.

[15] J. H. Choi, J. M. Gimble, K. Lee et al., “Adipose tissue engineering for soft tissue regeneration,” *Tissue Engineering Part B: Reviews*, vol. 16, no. 4, pp. 413–426, 2010.

[16] J. Tongers, D. W. Losordo, and U. Landmesser, “Stem and progenitor cell-based therapy in ischaemic heart disease: promise, uncertainties, and challenges,” *European Heart Journal*, vol. 32, no. 10, pp. 1197–1206, 2011.

[17] S. B. Adams Jr., M. A. Thorpe, B. G. Parks, G. Aghazarian, E. Allen, and L. C. Schon, “Stem cell-bearing suture improves Achilles tendon healing in a rat model,” *Foot & Ankle International*, vol. 35, no. 3, pp. 293–299, 2014.

[18] S. M. Cronk, M. R. Kelly-Goss, H. C. Ray et al., ”Adipose-derived stem cells from diabetic mice show impaired vascular stabilization in a murine model of diabetic retinopathy,” *Stem Cells Translational Medicine*, vol. 4, no. 5, pp. 459–467, 2015.

[19] S. Verit, W. Andre, N. Aouassar et al., “Human adipose-derived mesenchymal stem cells in cell therapy: safety and feasibility in different “hospital exemption” clinical applications,” *PLoS One*, vol. 10, no. 10, p. e0139566, 2015.

[20] H. H. Ceylan, K. Bilõsl, N. Buyukpinarbasili et al., “Can chondral healing be improved following microfracture? The effect of adipocyte tissue derived stem cell therapy,” *The Knee*, vol. 23, no. 3, pp. 442–449, 2016.

[21] C. R. Fellows, C. Matta, R. Zakany, I. M. Khan, and A. Mobasheri, “Adipose-derived cells (stromal vascular fraction) transplanted for orthopedical or neurological purposes: are they safe enough?,” *Stem Cells International*, vol. 2016, 5 pages, 2016.

[22] E. Raposo, S. Bonomini, and F. Calderazzi, “Isolation of autologous adipose tissue-derived mesenchymal stem cells for bone repair,” *Orthopaedics & Traumatology: Surgery & Research*, vol. 102, no. 7, pp. 909–912, 2016.

[23] K. Siennicka, A. Zolocinska, K. Stepien et al., “Adipose-derived cells (stromal vascular fraction) transplanted for orthopedical or neurological purposes: are they safe enough?,” *Stem Cells International*, vol. 2016, 5 pages, 2016.

[24] E. Kronist-Pál, A. Czibula, Z. Gyuris et al., “Characterization and therapeutic application of canine adiposemesenchymal stem cells to treat elbow osteoarthritis,” *Canadian Journal of Veterinary Research*, vol. 81, no. 1, pp. 73–78, 2017.

[25] L. Mei, B. Shen, P. Ling et al., “Culture-expanded allogenic adipose tissue-derived stem cells attenuate cartilage degeneration in an experimental rat osteoarthritis model,” *PLoS One*, vol. 12, no. 4, article e0176107, 2017.

[26] J. Freitag, D. Li, J. Wickham, K. Shah, and A. Tenen, “Effect of autologous adipose-derived mesenchymal stem cell therapy in the treatment of a post-traumatic chondral defect of the knee,” *BMJ Case Reports*, vol. 2017, 2017.

[27] P. Katajisto, J. Döhla, C. L. Chaffer et al., “Stem cells. Asymmetric apportioning of aged mitochondria between daughter cells is required for stemness,” *Science*, vol. 348, no. 6232, pp. 340–343, 2015.

[28] M. B. Schultz and D. A. Sinclair, “When stem cells grow old: phenotypes and mechanisms of stem cell aging,” *Development*, vol. 143, no. 1, pp. 3–14, 2016.

[29] E. U. Alt, C. Senst, S. N. Murthy et al., “Aging alters tissue resident mesenchymal stem cell properties,” *Stem Cell Research*, vol. 8, no. 2, pp. 215–225, 2012.

[30] B. Y. Lee, J. A. Han, J. S. Im et al., “Senescence-associated beta-galactosidase is lysosomal beta-galactosidase,” *Aging Cell*, vol. 5, no. 2, pp. 187–195, 2006.

[31] E. J. Moerman, K. Teng, D. A. Lipschitz, and B. Lecka-Czernik, “Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-gamma2 transcription factor and TGF-beta/BMP signaling pathways,” *Aging Cell*, vol. 3, no. 6, pp. 379–389, 2004.

[32] B. T. Estes, A. W. Wu, R. W. Storms, and F. Guilak, “Extended passaging, but not aldehyde dehydrogenase activity, increases the chondrogenic potential of human adipose-derived adult stem cells,” *Journal of Cellular Physiology*, vol. 209, no. 3, pp. 987–995, 2006.

[33] S. Zhou, J. S. Greenberger, M. W. Epperly et al., “Age-related intrinsic changes in human bone-marrow-derived
mesenchymal stem cells and their differentiation to osteoblasts,” Aging Cell, vol. 7, no. 3, pp. 335–343, 2008.

[34] L. W. C. Ng, S. K. Yip, H. K. Wong et al., “Adipose-derived stem cells from pregnant women show higher proliferation rate unrelated to estrogen,” Human Reproduction, vol. 24, no. 5, pp. 1164–1170, 2009.

[35] A. C. Pandey, J. A. Semon, D. Kaushal et al., “MicroRNA profiling reveals age-dependent differential expression of nuclear factor κB and mitogen-activated protein kinase in adipose and bone marrow-derived human mesenchymal stem cells,” Stem Cell Research & Therapy, vol. 2, no. 6, p. 49, 2011.

[36] M. S. Choudhery, M. Badowski, A. Muise, J. Pierce, and D. T. Harris, “Donor age negatively impacts adipose tissue-derived mesenchymal stem cell expansion and differentiation,” Journal of Translational Medicine, vol. 12, no. 1, p. 8, 2014.

[37] K. Kornicka, K. Marycz, K. A. Tomaszewski, M. Marędziak, and A. Śmieszek, “The effect of age on osteogenic and adipogenic differentiation potential of human adipose derived stromal stem cells (hASCs) and the impact of stress factors in the course of the differentiation process,” Oxidative Medicine and Cellular Longevity, vol. 2015, pp. 1–20, 2015.

[38] S. Jiang, H. K. Haider, R. P. H. Ahmed, N. M. Idris, A. Salim, and M. Ashraf, “Transcriptional profiling of young and old mesenchymal stem cells in response to oxygen deprivation and reparability of the infarcted myocardium,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 3, pp. 582–596, 2008.

[39] A. Efimenko, E. Starostina, N. Kalinina, and A. Stolzing, "Angiogenic properties of aged adipose derived mesenchymal stem cells after hypoxic conditioning," Journal of Translational Medicine, vol. 9, no. 1, p. 10, 2011.

[40] A. S. Tarnawski, A. Ahluwalia, and M. K. Jones, "Angiogenesis in gastric mucosa: an important component of gastric erosion and ulcer healing and its impairment in aging," Journal of Gastroenterology and Hepatology, vol. 4, pp. 112–123, 2014.

[41] M. Montali, F. M. Panvini, S. Barachini et al., "Human adult mesangiogenic progenitor cells reveal an early angiogenic potential, which is lost after mesengenic differentiation," Stem Cell Research & Therapy, vol. 8, no. 1, p. 106, 2017.